Novartis deal on the rocks, page-60

Someone please explain this

If the primary endpoint was 43% reduction in mortality why would the DSMB continue the trial at the first and second interim analysis if it didn't meet at least 43% at those points

To me it looks like the 3rd interim analysis had a reduced mortality of less than 43% which would make achieving the endpoint impossible so it ended for further review.

the DSMB said it didn't believe the endpoints will be reached (obviously of any one of the interim analysis had less than a 43% reduction in mortality)
it didn't state the trial ended for futility explicitly